Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Arcus Biosciences (NYSE: RCUS).The analyst comments "It was likely more ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE